REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 189 filers reported holding REATA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.71 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $26,039,259 | +12.3% | 255,387 | +0.1% | 1.41% | +3.1% |
Q1 2023 | $23,186,237 | +15.9% | 255,018 | -51.6% | 1.37% | +10.6% |
Q4 2022 | $19,999,646 | +80.6% | 526,445 | +19.5% | 1.24% | +77.0% |
Q3 2022 | $11,075,000 | +45.0% | 440,718 | +75.4% | 0.70% | +58.4% |
Q2 2022 | $7,636,000 | +6.9% | 251,268 | +15.3% | 0.44% | +39.9% |
Q1 2022 | $7,142,000 | +55.4% | 218,006 | +25.1% | 0.32% | +95.1% |
Q4 2021 | $4,597,000 | -83.7% | 174,316 | -37.9% | 0.16% | -83.4% |
Q3 2021 | $28,253,000 | -20.9% | 280,816 | +11.2% | 0.98% | -16.4% |
Q2 2021 | $35,733,000 | +42.5% | 252,476 | +0.4% | 1.17% | +40.6% |
Q1 2021 | $25,074,000 | +178.8% | 251,497 | +336.4% | 0.83% | +96.2% |
Q2 2020 | $8,992,000 | -37.3% | 57,635 | -42.0% | 0.42% | -52.8% |
Q1 2020 | $14,344,000 | -28.3% | 99,374 | +1.6% | 0.90% | +10.0% |
Q4 2019 | $19,994,000 | -6.8% | 97,804 | -63.4% | 0.82% | -14.0% |
Q3 2019 | $21,463,000 | -36.8% | 267,321 | -25.7% | 0.95% | -29.6% |
Q2 2019 | $33,963,000 | +10.4% | 359,970 | 0.0% | 1.35% | +9.4% |
Q1 2019 | $30,767,000 | +12.8% | 359,970 | -26.0% | 1.23% | -3.3% |
Q4 2018 | $27,276,000 | -24.9% | 486,210 | +9.4% | 1.28% | +3.9% |
Q3 2018 | $36,342,000 | +113.5% | 444,492 | -8.7% | 1.23% | +98.9% |
Q2 2018 | $17,021,000 | +76.1% | 486,741 | +3.3% | 0.62% | +62.8% |
Q1 2018 | $9,663,000 | -25.7% | 471,114 | +2.6% | 0.38% | -26.7% |
Q4 2017 | $13,004,000 | -11.6% | 459,184 | -2.9% | 0.52% | -15.7% |
Q3 2017 | $14,712,000 | +58.2% | 473,051 | +60.9% | 0.61% | +51.4% |
Q2 2017 | $9,300,000 | +49.5% | 293,927 | +7.0% | 0.40% | +42.1% |
Q1 2017 | $6,222,000 | +24.2% | 274,692 | +19.7% | 0.28% | +19.2% |
Q4 2016 | $5,011,000 | -17.1% | 229,559 | +0.1% | 0.24% | -22.4% |
Q3 2016 | $6,048,000 | +67.9% | 229,440 | +25.8% | 0.31% | +52.5% |
Q2 2016 | $3,602,000 | – | 182,390 | – | 0.20% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CPMG Inc | 3,063,567 | $298,453,000 | 49.63% |
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 150,000 | $14,613,000 | 19.62% |
Corriente Advisors, LLC | 300,000 | $29,226,000 | 14.82% |
Prosight Management, LP | 114,554 | $11,160,000 | 5.31% |
MADDEN SECURITIES Corp | 43,927 | $4,279,000 | 3.18% |
LBJ Family Wealth Advisors, Ltd. | 30,368 | $2,958,000 | 2.24% |
Biondo Investment Advisors, LLC | 99,652 | $9,708,000 | 2.10% |
Cormorant Asset Management, LP | 450,000 | $43,839,000 | 1.69% |
Duquesne Family Office | 543,901 | $52,987,000 | 1.54% |
AWH Capital, L.P. | 9,500 | $925,000 | 1.30% |